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a b s t r a c t
Objective: To assess the effects of L-dopa and deep brain stimulation of the subthalamic
nucleus (DBS-STN) on saccadic eye movements in patients with Parkinson's disease (PD).
Methods: Visually and internally guided horizontal saccades were evaluated using a sac-
cadometer in 64 patients with advanced PD and 48 healthy controls. Forty-four pharmaco-
logically treated patients were assessed in their ‘‘med-off’’ (OFF) and ‘‘med-on’’ (ON) status,
whereas 20 DBS-STN treated patients were assessed in their ‘‘med-off, stim-off’’ (OFF) and
‘‘med-off, stim-on’’ (ON) status.
Results: In all PD patients the saccades in the OFF status were delayed, slower and smaller
( p < 0.01) than in controls. In pharmacologically treated patients all studied parameters
showed tendency to worsen in the ON status as compared to the OFF status. In contrast,
activating DBS-STN showed tendency to improve all studied parameters. Comparison of the
studied saccade parameters between the ON status of DBS-STN treated patients, ON status
of the pharmacologically treated patients and the controls showed that 73% of these
parameters in the DBS-STN treated patients were similar as in the controls. While in the
pharmacologically treated patients only 26% of these parameters were similar as in the
controls.
Conclusion: This prospective study comparing the inﬂuence of L-dopa and DBS-STN on
saccades in advanced PD showed contrasting results between these two treatments; the
majority of the studied parameters in patients on DBS-STN were similar as in the controls.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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There have been several reports describing abnormalities of
eye movements in Parkinson's disease (PD), such as difﬁculties
in stabilizing the image on the retina, or difﬁculties in
redirecting the line of sight to a new object (visually or
internally guided saccades). Both difﬁculties can be affected
either by the disease itself or by treatment [1].
Saccades are more easily quantiﬁed and less dependent on
biomechanical parameters than limb movements, thus, they
might be a more appropriate for studying movement control in
PD. In this disease, measurements of repetitive saccadic
movements, in contrast to measurements of limb movements,
can be easily performed even in OFF status [2,3]. Saccadic
abnormalities in PD essentially resemble somatomotor symp-
toms, being characterized by increased reaction time, de-
creased amplitude and decreased velocity, and consequently
may reﬂect hypometria and bradykinesia [4].
Previous studies on the effects of deep brain stimulation of
the subthalamic nucleus (DBS-STN) or L-dopa on saccades
have led to varying results and their clinical signiﬁcance was
not clear [2,5–8]. We compared the inﬂuence of L-dopa and
DBS-STN on saccades in patients with advanced PD, using a
prospective protocol.
2. Material and methods
2.1. Study participants
The participants were recruited from the Movement Disorders
outpatient clinic of the Department of Neurology. Forty-four of
the study patients had advanced PD treated only with L-dopa
(Hoehn and Yahr scale off drug, 4.1  0.2) and 20 were
additionally treated with bilateral DBS-STN, all implanted
using the same surgical protocol (mean follow-up since DBS-
STN procedure, 2 years; H&Y off drug, 4.0  0.2) [8,9]. Exclusion
criteria were as follows: cognitive dysfunction (<24 points on
the Mini-Mental State Examination, MMSE), moderate-to-
severe depression (>16 points on the Hamilton Rating Scale
for Depression, HRSD) [10], color blindness (score <0.1 at the
best corrected visual performance, using a standard Snellen
Chart), red color vision impairment using the Ishihara Color
Test, and severe eye-movement impairments upon neurolog-
ical examination.
Forty-eight healthy subjects matched by age and gender (28
males; mean age 60  8) served as controls.
All participants provided written, informed consent. Ethical
approval was given by the institutional review board.
2.2. Study design
Social and demographic characteristics, medical history
including age at disease onset and course of disease as well
as L-dopa equivalent daily dose (LEDD) were recorded from all
participants during the initial visit and neurological examina-
tion was performed, including visual acuity, color distinction
and eye movement assessment. Additionally, study subjects
were rated on MDS-UPDRS part III in their best clinical ONstate–after intake of 1.5 times the equivalent of their morning
medication dose – and ﬁlled out the quality of life PDQ-39
questionnaire. PD was staged according to the Hoehn-Yahr
scale (H&Y) [8], and PD subtype (tremor-dominant vs.
bradykinesia, postural instability and gait difﬁculty, PIGD)
[11] was identiﬁed in each patient.
During the study period, PD subjects were examined twice,
in their clinically deﬁned L-dopa-OFF and ON status, on 2
consecutive days. Following classical guidelines, the ﬁrst
assessment of pharmacologically treated patients was per-
formed in the clinically deﬁned OFF-status after drug
withdrawal for at least 12 h for L-dopa and 48 h for other
antiparkinsonian drugs (‘‘med off’’) [12,13]. The second
assessment was carried out approximately 45–60 min after
L-dopa intake (1.5 times the equivalent of morning medication
dose) in the best ON status (deﬁned as the status when patient
and examiner agreed that the patient's best ON was attained)
[14]. The assessment of the DBS-STN patients was performed
in the clinically deﬁned OFF-status as in the previous group
(‘‘med off’’), with the stimulator switched on (‘‘stim on’’) and
repeated 30 min after switching the neurostimulator off, in the
stimulation OFF state (‘‘med off’’ and ‘‘stim off’’) [12,13]. The
assessment of patients in their ON (pharmacologically treated
patients: ‘‘med on’’; DBS-STN patients: ‘‘med off’’ and ‘‘stim
on’’) and OFF states (pharmacologically treated patients: ‘‘med
off’’; DBS-STN patients: ‘‘med off’’ and ‘‘stim off’’) involved
both neurological examination (including MDS-UPDRS part III
assessment) and saccadic eye-movement recording.
In control subjects, only one saccadic eye-movement
recording was performed.
2.3. Saccade assessment
The participants were seated in a comfortable armchair, one
meter away from a board with light-emitting diodes along a
horizontal line. Saccadic eye movements were recorded using
a miniaturized infra-red 1 kHz saccadometer, low pass ﬁltered
at 250 Hz with 12 bit resolution (Ober Consulting, Poznan,
Poland) [15]. While the device was mounted on the subject's
forehead, resting on the bridge of the nose, ﬁve built-in low-
power lasers projected red 13 cd m2 spots subtending some
0.1 degrees in horizontal line in the midline at 20 degrees
from central vision. As stimuli moved exactly with the head,
no head-restraint was necessary, unless desired by the
patient.
Participants underwent 3 experimental runs in a random
order. Saccades were determined to begin when eye velocity
was greater than 208/s. Of all performed saccades, only
centrifugal visually and internally guided saccades were
analyzed. Each experimental run was preceded by a number
of preliminary saccades (usually 10, toward a 10-deg or 20-deg
lateral target that appeared randomly right or left), used to
calibrate the device. Each experimental run lasted 10–15 min
and participants rested between trials to minimize fatigue.
For visually guided saccades, a test with a gap paradigm
was performed. Participants were instructed to initially ﬁxate a
central ﬁxation point illuminated for 3.5 s, then to make a
saccade toward a 10-deg or 20-deg lateral target that appeared
randomly right or left 200 ms (temporal gap) after the
disappearance of the ﬁxation point [5]. Participants were cued
Table 1 – Demographic and clinical characteristics of PD patients.
Parameter DBS-STN treated patients
n = 20
Pharmacologically treated patients
n = 44
p
Male/female ratio 6/14 20/24 n.s.
Age (years)
(mean  SD)
63
(7)
65
(10)
n.s.
Disease duration (years)
(mean  SD)
11.9
(5.42)
10.77
(3.85)
n.s.
PIGD (%) 85% 68.18% n.s.
LEDD [mg]
(mean  SD)
454
(334.99)
1061.14
(326.65)
0.0001
MDS-UPDRS III (OFF status)
(mean  SD)
34.15
(7.17)
47.47
(10.09)
<0.00001
PDQ-39
(mean  SD)
44.85
(26.61)
68.16
(23.05)
0.0016
n.s., not signiﬁcant; PIGD, postural instability and gait difﬁculty subtype of the disease; LEDD, L-dopa equivalent daily dose; MDS-UPDRS III,
Uniﬁed Parkinson's Disease Rating Scale. Part III (OFF status for DBS-STN treated patients means ‘‘med-off and stim-off’’ and for
pharmacologically treated patients means ‘‘med-off’’); PDQ-39, the Parkinson's disease questionnaire.
Table 2 – Saccadic parameters in PD patients in the OFF status and controls.
Visually guided saccades DBS-STN treated patients
n = 20
(A)
Pharmacologically treated patients
n = 44
(B)
Controls
n = 48
(C)
p
Latency [ms] 325.7
(116.2)
256.8
(68.5)
229.8
(38.5)
(A–C) < 0.01
Amplitude 108 7.6
(2.5)
8.9
(2.3)
9.7
(1.9)
(A–C) < 0.01
Amplitude 208 12.6
(4.3)
15.3
(4.1)
17.9
(4.1)
(A–C) < 0.01
(B–C) < 0.01
Peak velocity 108 [8/s] 224.2
(66.6)
303.3
(105.0)
312.1
(73.4)
(A–C) < 0.01
(A,B) < 0.01
Peak velocity 208 [8/s] 262.7
(81.6)
360.9
(118.0)
381.0
(94.0)
(A–C) < 0.01
(A,B) < 0.01
Antisaccades
[n] 34 38 61 (A–C) < 0.01
(B–C) < 0.01
Latency [ms] 520.9
(130.4)
515.9
(247.2)
324.9
(61.6)
(A–C) < 0.01
(B–C) < 0.01
Peak velocity [8/s] 202.2
(53.1)
240.9
(85.2)
291.8
(87.0)
(A–C) < 0.01
(B–C) = 0.03
Memory-guided saccades
[n] 25 22 47 (A–C) = 0.02
(B–C) < 0.01
Latency 108 [ms] 652.1
(331.1)
571.0
(307.5)
408.5
(200.0)
(A–C) = 0.01
(B–C) = 0.03
Latency 208 [ms] 521.4
(225.6)
566.7
(215.2)
410.4
(179.6)
(B–C) = 0.01
Amplitude 108 8.8
(2.0)
10.2
(3.9)
11.3
(3.4)
(A–C) < 0.01
Amplitude 208 16.7
(1.8)
16.0
(5.8)
20.5
(6.3)
(B–C) < 0.01
Peak velocity 108 [8/s] 199.1
(45.5)
241.9
(125.5)
284.4
(96.0)
(A–C) = 0.01
(B–C) = 0.02
Peak velocity 208 [8/s] 215.7
(95.6)
288.0
(130.1)
356.8
(114.4)
(A–C) < 0.01
(B–C) < 0.01
Data are mean (SD).
p < 0.05.
n, number of saccades properly accomplished (%).
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saccades total) and latency, amplitude, as well as peak saccadic
velocity were evaluated. The following visually guided param-
eters were studied: amplitudes for 10 or 20 degree-saccades,
latency and peak saccadic velocity for 10 or 20 degrees.
The internally guided saccades were tested using anti-
saccadic and memory-guided tests for which subjects were
tested for 60 trials, 30 saccades in each direction in a random
order.
For the antisaccadic test, the same stimulus condition as in
the visually guided saccade test was used, but participants
were instructed that after the appearance of the eccentric
target (10-deg or 20-deg), they were to generate a saccade away
from it to its mirror location [5].
For the memory-guided test, participants were instructed
to initially ﬁxate the central ﬁxation point illuminated for 4.5 s.
A 50 ms ﬂash then appeared, randomly right or left with
unpredictable eccentricity (10-deg or 20-deg). After the ﬂash,
the central ﬁxation point remained illuminated for 7 s, and
participants were supposed to keep their eyes on the centralTable 3 – Saccadic parameters in DBS-STN treated patients and
status.
Variable DBS-STN treated patients
n = 20
OFF ON 
Visually guided saccades
Latency [ms] 325.7
(116.2)
246.3
(57.3)
Amplitude 108 7.6
(25)
9.1
(1.9)
Amplitude 208 12.6
(4.3)
15.7
(4.2)
Peak velocity 108 [8/s] 224.2
(66.6)
276.8
(72.9)
Peak velocity 208 [8/s] 262.7
(81.6)
326.9
(89.4)
Antisaccades
[n] 34% 28% 
Latency [ms] 520.9
(130.4)
430.5
(131.2)
Peak velocity [8/s] 202.2
(53.1)
273.4
(83.6)
Memory-guided saccades
[n] 25% 30% 
Latency 108 [ms] 652.1
(331.1)
455.8
(139.5)
Latency 208 [ms] 521.4
(225.6)
417.1
(131.3)
Amplitude 108 8.8
(2.0)
9.6
(1.3)
Amplitude 208 16.7
(1.8)
17.3
(2.5)
Peak velocity 108 [8/s] 199.1
(45.5)
239.9
(77.8)
Peak velocity 208 [8/s] 215.7
(95.6)
267.5
(83.7)
Data are presented as mean (SD).
n.s., not signiﬁcant.
n, percentage of saccades properly accomplished.ﬁxation point during the entire delay. Participants were
required to move their eyes toward the memorized location
of the ﬂash as soon as the central ﬁxation point was switched
off. Two seconds later, a target with the same location as the
ﬂash was illuminated to allow the corrective saccade to be
executed, if needed [5]. The percentage, latency, amplitude
(memory-guided saccades) and peak saccadic velocity of properly
accomplished internally-guided saccades were evaluated.
2.4. Statistics
Due to violated normality assumption in the data distribu-
tions, all parameters were logarithmically transformed.
Descriptive statistics provided means, standard deviations
and standard errors for all variables. Hypotheses concerning
the differences between ON and OFF were tested by means of a
two-factor analysis of variance with one repeated-measures
factor (ON vs. OFF).
Interaction among the three groups was tested by means of
one factor analysis of variance (Anova). In the case of pharmacologically treated patients in their ON and OFF
p Pharmacologically treated
patients
n = 44
p
OFF ON
<0.01 256.8
(68.5)
307.2
(82.7)
<0.01
n.s. 8.9
(2.3)
9.7
(3.2)
n.s.
n.s. 15.3
(4.1)
14.4
(5.4)
n.s.
n.s. 303.3
(105.0)
278.6
(117.8)
n.s.
n.s. 360.9
(118.0)
323.6
(145.8)
n.s.
n.s. 38% 32% n.s.
n.s. 515.9
(247.2)
509.9
(199.5)
n.s.
n.s. 240.9
(85.2)
213.5
(71.9)
n.s.
n.s. 22% 22% n.s.
n.s. 571.0
(307.5)
487.9
(212.9)
n.s.
n.s. 566.7
(215.2)
440.9
(152.5)
n.s.
n.s. 10.2
(3.9)
10.1
(3.6)
n.s.
n.s. 16.0
(5.8)
15.6
(3.5)
n.s.
n.s. 241.9
(125.5)
203.3
(64.4)
n.s.
<0.01 288.0
(130.1)
257.8
(97.4)
n.s.
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honest difference test). Signiﬁcance was set at the 0.05 level.
SPSS 21 software was used to analyze the data (IBM Corp., 2012).
3. Results
The characteristics of the PD patients are presented in Table 1.
DBS-STN patients required a signiﬁcantly lower L-dopa
equivalent daily dose, presented with better motor control
in their OFF status measured by MDS-UPDRS part III and had
better quality of life as measured by the PDQ-39. Each group of
PD patients in the OFF status differed from the controls in
almost all parameters of both visually and internally guided
saccades (Table 2).
Table 3 summarizes all studied pre- and post-therapeutic
saccade parameters. In pharmacologically treated patients all
parameters showed tendency to worsen in their ON status
(visually guided saccades: delayed, smaller and slower;
internally guided saccades: less number of properly accom-
plished saccades, smaller and slower) as compared to OFFTable 4 – Comparison of saccadic parameter changes between 
patients in their ON status and in healthy controls.
Variable Groups 
Visually guided saccades
Latency [ms] DBS-STN Controls 
L-Dopa Controls 
Amplitude 108 DBS-STN Controls 
L-Dopa Controls 
Amplitude 208 DBS-STN Controls 
L-Dopa Controls 
Peak velocity 108 [8/s] DBS-STN Controls 
L-Dopa Controls 
Peak velocity 208 [8/s] DBS-STN Controls 
L-Dopa Controls 
Antisaccades
[%] DBS-STN Controls 
L-Dopa Controls 
Latency [ms] DBS-STN Controls 
L-Dopa Controls 
Peak velocity [8/s] DBS-STN Controls 
L-Dopa Controls 
Memory-guided saccades
[%] DBS-STN Controls 
L-Dopa Controls 
Latency 108 [ms] DBS-STN Controls 
L-Dopa Controls 
Latency 208 [ms] DBS-STN Controls 
L-Dopa Controls 
Amplitude 108 DBS-STN Controls 
L-Dopa Controls 
Amplitude 208 DBS-STN Controls 
L-Dopa Controls 
Peak velocity 108 [8/s] DBS-STN Controls 
L-Dopa Controls 
Peak velocity 208 [8/s] DBS-STN Controls 
L-Dopa Controls 
[%], percentage of saccades properly accomplished.status. Activating DBS-STN showed tendency to improve all
studied parameters (visually guided saccades: decreased
latency, increased amplitude, increased peak saccadic veloci-
ty; internally guided saccades: higher number of properly
accomplished saccades, increased amplitude, increased peak
saccadic velocity). Comparison of the studied saccade param-
eters between the ON status of DBS-STN treated patients, ON
status of the pharmacologically treated patients and the
controls showed that as many as 73% of the studied
parameters in the DBS-STN treated patients reached similar
values as in the controls, as against 26% in pharmacologically
treated patients (Table 4).
4. Discussion
This study comparing the inﬂuence of L-dopa and DBS-STN on
saccades in advanced PD, showed contrasting results. DBS-
STN, as compared to L-dopa improved almost all the studied
saccadic parameters; and the results for the majority (73%) of
them were similar to those in the controls.DBS-STN treated patients in their ON status. L-Dopa treated
Mean difference Mean error p
.02 .03 .826
.12 .02 <.001
.03 .03 .556
.05 .02 .026
.06 .03 .143
.10 .03 <.001
.06 .03 .185
.06 .03 .033
.07 .03 .098
.09 .03 .004
.40 .09 <.001
.41 .07 <.001
.11 .04 .010
.18 .03 <.001
.02 .04 .805
.13 .03 <.001
.13 .12 .536
.42 .10 <.001
.09 .05 .103
.08 .04 .135
.06 .04 .313
.05 .04 .454
.06 .03 .095
.06 .02 .068
.07 .03 .033
.11 .02 <.001
.08 .04 .095
.17 .03 <.001
.11 .04 .024
.17 .04 <.001
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on saccadic eye movements in PD patients have been published
[2,3,5,6]. The presented study included a larger group of patients
with the advanced PD than in previous research. Furthermore,
prior studies accepted concomitant treatment with antiparkin-
sonian drugs during the procedure [5], the majority applied short
‘‘stim off’’ time (up to 15 min) and had a more limited battery of
tests for saccadic characteristics [2]. Unlike the current study, the
other studies did not compare the patients' results to those of
healthy controls. The effect of DBS-STN can be explained by its
impact on the correction of excitability of the cortical areas
involved in the saccades generation.
The presented study showed that L-dopa treatment showed
a tendency to deteriorate almost all analyzed saccadic
parameters. It is difﬁcult to compare our results with previous
reports, since in those studies the patients were mostly in their
early stage of the disease [7,8,15].
In addition, the prior studies included smaller groups of
patients (most included less than 20 cases) [7,8,15], they
considered only 3 or less saccadic parameters [4,7,8,15], in two
studies both L-dopa and dopaminergic agonists were accepted
[8,15], and ﬁnally, the same dosage of L-dopa was applied
irrespectively of the stage of the disease [7]. It is well known
that L-dopa effects of treatment depend on the stage of the
disease; it loses its efﬁcacy during long-term therapy. In
advanced PD the presence of complications of L-dopa therapy
is predominant. It is possible that detrimental effect of L-dopa
on saccadic movements is part of late adverse effect proﬁle of
this drug.
Limitations of the present study include the fact that the
same PD subjects were not assessed in all four intervention
states [medication/DBS] (OFF OFF; OFF ON; ON OFF; ON ON)
using a standardized dosage of L-dopa. In addition, the order of
L-dopa OFF and ON states or STN-OFF and ON states was not
randomized. PD patients tend to fatigue easily when partici-
pating in series of assessments, and saccade performance in
particular may be affected by fatigue. However, for the sake of
practicality classical guidelines of patient examination used in
numerous other studies were reproduced here [12,13], and, as
speciﬁed in Methods, PD patients rested between trials to
minimize fatigue. Lack of examiner-blinding in the subject-
OFF or ON status is another potential limitation. However, the
measurement method was highly objective. Finally, the study
design was limited to horizontal saccade analysis; however,
execution of vertical and horizontal saccades involves a
similar ﬁnal pathway [1].
In conclusion, this study conﬁrmed the saccadic abnor-
malities in advanced PD and disclosed remarkably conﬂicting
effects of L-dopa and DBS-STN. DBS-STN improved almost all
the studied saccadic parameters; and the majority of them
reached similar values as those in the controls. Studying the
effects of L-dopa and DBS-STN on the ocular motor system may
shed more light on the pathogenesis underlying eye move-
ment abnormalities in neurodegenerative disorders. The
applied protocol, even if time consuming, can be considered
in the clinical setting as a method of a long-term monitoring of
DBS-STN effectiveness. Systematic monitoring of saccadic
proﬁle in DBS-STN patients can detect the waning of the
beneﬁts of DBS-STN in long-term treatment. Further studies
are needed.5. Conclusion
This prospective study comparing the inﬂuence of L-dopa and
DBS-STN on saccades in advanced PD showed contrasting
results between these two treatments; the majority of the
studied parameters in patients on DBS-STN were similar as in
the controls.
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